Kolmar Korea Co., Ltd. (161890.KS)
Sejong, GW, KR
Kolmar Korea Co., Ltd. researches, develops, produces, and sells beauty and health products in South Korea and internationally. It offers skincare cosmetic products, including toners, lotions, ampoules, essences, creams, mask sheets, mask packs, and lip balms; fragrance products, such as perfumes, and cleansing products; body and hair products; and color cosmetic products comprising makeup bases, primers, foundation and concealers, cushion foundations, and mascaras. The company also provides powder base products, such as eye shadows, powder pacts, highlighters, blushers, shadings, loose powders, jelly powders, wet powders, multi-color concurrent forming, gradations, marble teracotas, hair cushions, essence powders, bubble salts, eyebrow pencils, highlighters, etc.; and oil & emulsification base products, including lip sticks, lip balms, lip glosses, tints, essence pacts, stick foundations, sun sticks, skin covers, gel eyeliners, marble essence pacts, core sticks, two-tone sticks, marble sticks, serum sticks, eye sticks, balms, concealers, etc. In addition, it offers PLATIT147, a health and beauty production platform. Further, the company engages in the real estate rental business and manufacturing of plastic molded containers. Kolmar Korea Co., Ltd. was founded in 1990 and is headquartered in Sejong City, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.20% | +14.40% | +26.87% | +38.26% | +54.48% | +53.06% | +21.92% | +149.63% | +75.92% | +7.06% | +305.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 16 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+11.0% ★ Q1'26: +11.5% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%+39.0% ★ Q1'26: +241.0% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+5.8% ★ Q1'26: +3.9% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+8.8% Q1'26: +10.8% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+7.4% Q1'26: +9.4% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%+0.4% Q1'26: +32.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×3.58× Q1'26: 3.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 22 EPS Ana. |
Dec 2027 24 Rev. Ana. 24 EPS Ana. |
Dec 2028 11 Rev. Ana. 12 EPS Ana. |
Dec 2029 23 Rev. Ana. 22 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
535.85B
est: 541.49B (-1.0%)
|
667.47B
est: 662.87B (+0.7%)
|
821.62B
est: 820.84B (+0.1%)
|
1.36T
est: 1.36T (-0.1%)
|
1.54T
est: 1.54T (-0.1%)
|
1.32T
est: 1.33T (-0.9%)
|
1.59T
est: 1.58T (+0.5%)
|
1.87T
est: 1.87T (+0.0%)
|
2.16T
est: 2.15T (+0.2%)
|
2.45T
est: 2.47T (-0.8%)
|
2.72T
est: 2.72T (+0.1%)
|
2.99T
2.95T – 3.02T
+9.9% YoY
|
3.24T
3.01T – 3.42T
+8.3% YoY
|
3.47T
3.32T – 3.59T
+7.2% YoY
|
4.16T
3.98T – 4.30T
+19.7% YoY
|
| EBITDA |
70.43B
est: 65.09B (+8.2%)
|
84.12B
est: 79.69B (+5.6%)
|
85.17B
est: 98.68B (-13.7%)
|
130.82B
est: 163.48B (-20.0%)
|
159.24B
est: 185.36B (-14.1%)
|
320.65B
est: 160.31B (+100.0%)
|
156.40B
est: 189.82B (-17.6%)
|
126.27B
est: 224.21B (-43.7%)
|
169.81B
est: 258.72B (-34.4%)
|
278.26B
est: 430.51B (-35.4%)
|
343.74B
est: 473.44B (-27.4%)
|
520.42B
514.12B – 526.75B
+9.9% YoY
|
563.86B
523.67B – 595.57B
+8.3% YoY
|
604.72B
578.92B – 625.84B
+7.2% YoY
|
723.93B
693.04B – 749.21B
+19.7% YoY
|
| EBIT |
60.79B
est: 42.90B (+41.7%)
|
72.28B
est: 52.52B (+37.6%)
|
65.98B
est: 65.04B (+1.5%)
|
88.80B
est: 107.74B (-17.6%)
|
98.65B
est: 122.17B (-19.3%)
|
258.91B
est: 105.66B (+145.0%)
|
98.03B
est: 125.11B (-21.6%)
|
50.85B
est: 147.77B (-65.6%)
|
76.08B
est: 170.52B (-55.4%)
|
186.29B
est: 336.17B (-44.6%)
|
239.59B
est: 369.69B (-35.2%)
|
406.38B
401.46B – 411.32B
+9.9% YoY
|
440.30B
408.92B – 465.06B
+8.3% YoY
|
472.21B
452.06B – 488.70B
+7.2% YoY
|
565.29B
541.17B – 585.04B
+19.7% YoY
|
| Net Income |
45.48B
est: 51.78B (-12.2%)
|
53.08B
est: 60.49B (-12.3%)
|
47.26B
est: 55.90B (-15.4%)
|
42.31B
est: 42.39B (-0.2%)
|
29.06B
est: 33.65B (-13.6%)
|
160.27B
est: 54.24B (+195.5%)
|
35.81B
est: 50.20B (-28.7%)
|
-21.98B
est: 12.37B (-277.7%)
|
5.19B
est: 73.54B (-92.9%)
|
90.07B
est: 69.25B (+30.1%)
|
125.08B
est: 102.14B (+22.5%)
|
152.72B
133.79B – 183.10B
+49.5% YoY
|
182.32B
157.54B – 218.36B
+19.4% YoY
|
225.04B
212.56B – 235.26B
+23.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
47.89B
est: 51.26B (-6.6%)
|
54.25B
est: 62.76B (-13.6%)
|
65.68B
est: 77.71B (-15.5%)
|
127.07B
est: 128.75B (-1.3%)
|
135.53B
est: 145.98B (-7.2%)
|
132.42B
est: 126.25B (+4.9%)
|
155.53B
est: 149.49B (+4.0%)
|
178.45B
est: 176.57B (+1.1%)
|
186.94B
est: 203.76B (-8.3%)
|
227.55B
est: 230.33B (-1.2%)
|
252.23B
est: 253.30B (-0.4%)
|
278.44B
275.07B – 281.82B
+9.9% YoY
|
301.68B
280.18B – 318.64B
+8.3% YoY
|
323.54B
309.73B – 334.84B
+7.2% YoY
|
387.32B
370.79B – 400.85B
+19.7% YoY
|
| EPS |
2,155.00
est: 2,201.98 (-2.1%)
|
2,516.00
est: 2,572.38 (-2.2%)
|
2,240.00
est: 2,376.84 (-5.8%)
|
1,953.92
est: 1,802.52 (+8.4%)
|
1,284.50
est: 1,430.90 (-10.2%)
|
7,004.47
est: 2,306.58 (+203.7%)
|
1,565.10
est: 2,134.67 (-26.7%)
|
-960.67
est: 526.14 (-282.6%)
|
226.90
est: 3,127.05 (-92.7%)
|
3,813.02
est: 2,933.79 (+30.0%)
|
5,298.80
est: 4,327.22 (+22.5%)
|
6,469.68
5,667.70 – 7,756.87
+49.5% YoY
|
7,723.89
6,674.16 – 9,250.53
+19.4% YoY
|
9,533.70
9,004.87 – 9,966.60
+23.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| George Rivera | Chief Science Officer of Kolmar North American subsidiaries | — | male |
| Hyun-Gyu Choi | Chief Executive Officer, President & Director | — | male |
| Inki Park | Head of the R&D Center for North America | — | male |
| Philippe Warnery | Global Chief Commercial Officer | — | male |
| Sang-Geun Han | Vice President & Chairman | — | male |
| Yi-Pyo Hong | Senior MD of KMB & Director | — | male |
| Yongchul Hur | Chief Executive Officer of Kolmar Laboratories, Kolmar USA & CEO of North American subsidiaries | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 161890.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
